MedAlliance Swiss Medical Technology

medical devices

About

MedAlliance Swiss Medical Technology is a privately-owned company based in Nyon, Switzerland, with additional facilities in the USA, UK, Singapore, and Germany. Founded in 2008, the company employs between 51 and 200 people and generates annual revenues estimated between $5 million and $25 million, with some sources indicating figures up to $100 million. The company specializes in developing and commercializing drug-device combination products, particularly drug-eluting balloons (DEBs) for treating coronary and peripheral artery diseases. Their flagship product, the SELUTION SLR™ drug-eluting balloon catheter, utilizes microreservoir technology for sustained sirolimus release, enhancing drug delivery in cardiovascular procedures. MedAlliance's products are designed for use in various cardiovascular and endovascular interventions, providing therapeutic benefits without the need for permanent stents. In 2023, MedAlliance was acquired by Cordis, a Johnson & Johnson company, in a significant deal valued at approximately $1.135 billion.

Technologies

Outlook DigitalOcean Remote

Keywords

cardiovascular drug eluting balloons sirolimus coated balloons pta microreservoir technology peripheral artery disease ptca endovascular coronary interventions coronary artery disease healthcare medical equipment manufacturing medalliance swiss medical technology sirolimus eluting pta balloon catheter ce mark approved balloon catheter coronary intervention drug eluting medical devices catheterization arterial procedures interventional cardiology cardiovascular devices vascular access stent delivery angioplasty endovascular surgery percutaneous transluminal angioplasty

Location

5 Rue de Rive, Nyon, Vaud, Switzerland, 1260

Related Companies

Companies in the same industry